139516-64-6

Basic information

• Product Name: 1-(2-FLUOROBENZOYL)PIPERAZINE
• Synonyms: 1-(2-fluorobenzoyl)piperazine hydrochloride;MFCD14583048;ethyl 3-amino-3-(3-cyanophenyl)propanoate
• CAS NO: 139516-64-6
• Molecular Formula: C₁₁H₁₃FN₂O
• Molecular Weight: 208.24
• Mol File: 139516-64-6.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 357.1°C at 760 mmHg
• Flash Point: 169.8°C
• Appearance: /
• Density: 1.15g/cm³
• Vapor Pressure: 2.78E-05mmHg at 25°C
• Refractive Index: 1.544
• CAS DataBase Reference: 1-(2-FLUOROBENZOYL)PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-FLUOROBENZOYL)PIPERAZINE(139516-64-6)
• EPA Substance Registry System: 1-(2-FLUOROBENZOYL)PIPERAZINE(139516-64-6)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 139516-64-6(Hazardous Substances Data)

Usage

General Description

1-(2-Fluorobenzoyl)piperazine is a chemical compound with the molecular formula C11H12F2N2O. It is a piperazine derivative and contains a fluorobenzoyl group. 1-(2-FLUOROBENZOYL)PIPERAZINE is often used in medicinal chemistry and pharmaceutical research as a building block for the synthesis of various drugs and bioactive molecules. It has been studied for its potential antipsychotic and antihistaminic properties, as well as its ability to interact with serotonin receptors. Additionally, 1-(2-fluorobenzoyl)piperazine has been investigated as a potential ligand for imaging studies in positron emission tomography (PET) and single-photon emission computed tomography (SPECT) for studying neurological disorders.

InChI:InChI=1/C12H14N2O2/c1-2-16-12(15)7-11(14)10-5-3-4-9(6-10)8-13/h3-6,11H,2,7,14H2,1H3

Upstream product

• 828298-39-1 tert-butyl 4-(2-fluorobenzoyl)piperazine-1-carboxylate 
• 142-64-3 piperazine dihydrochloride 
• 107599-83-7 (2-fluorobenzoyl)imidazoline 
• 110-85-0 piperazine 
• 393-52-2 2-Fluorobenzoyl chloride 
• 445-29-4 o-fluoro-benzoic acid 
• 121-44-8 triethylamine 

Downstream Products

• 1226894-88-7 C₂₇H₃₁F₄N₅O₃ 
• 936240-89-0 (2-fluoro-phenyl)-[4-(4-nitro-isoquinolin-1-yl)-piperazin-1-yl]-methanone 
• 89292-78-4 1-(o-fluorobenzyl)piperazine 
• 139516-42-0 2-{3-[4-(2-Fluoro-benzoyl)-piperazin-1-yl]-propyl}-6,7,8,9-tetrahydro-4H-naphtho[2,3-b][1,4]oxazin-3-one 

Relevant articles and documents

Looking toward the Rim of the Active Site Cavity of Druggable Human Carbonic Anhydrase Isoforms

We report the synthesis and biochemical evaluation of a series of substituted 4-(4-aroylpiperazine-1-carbonyl)benzenesulfonamides (5a-s) developed as inhibitors of druggable carbonic anhydrase (CA) isoforms, as tools for the identification of new therapeu

A N, 6 diphenyl pyrimidine -4 - amine Bcr - Abl inhibitor and its preparation method and application (by machine translation)

The invention discloses a N, 6 diphenyl pyrimidine - 4 - amine Bcr - Abl inhibitor and its preparation method and application, the structural formula of the inhibitor for the wherein R is a single substituent or double-substituent, substituent is alkyl or halogen; R1 As a single substituent or double-substituent, substituent is alkyl or halogen. The series of inhibitors in vitro ABL1 kinase restraining effects, and can inhibit the proliferation of tumor cells, can be used for anti-tumor pharmaceutical preparation, in particular CML (chronic granulocytic leukemia) drug. The invention provides N, 6 diphenyl pyrimidine - 4 - amine Bcr - Abl inhibitor preparation method, raw materials are apt, mild reaction conditions, the reaction process is simple in operation, reagent used and cheap. (by machine translation)

Expanding the structural diversity of Bcr-Abl inhibitors: Hybrid molecules based on GNF-2 and Imatinib

In order to expand the structural diversity of Bcr-Abl inhibitors, twenty hybrids (series E and P) have been synthesized and characterized based on Imatinib and GNF-2. Their biological activities were evaluated in vitro against human leukemia cells. Most compounds exhibited potent antiproliferative activity against K562 cells, especially for compounds E4, E5 and E7. Furthermore, these new hybrids were also screened for Abl kinase inhibitory activity, and some of them inhibited Abl kinase with low micromolar IC50 values. In particular, compound P3 displayed the most potent activity with IC50 value of 0.017 μM comparable with that of Imatinib. Molecular docking studies indicated that these novel hybrids fitted well with the active site of Bcr-Abl. These results suggested the great potential of these compounds as novel Bcr-Abl inhibitors.